Literature DB >> 22364366

Factors predicting early- and long-term survival in patients undergoing extracorporeal membrane oxygenation (ECMO).

Seung Hyun Lee1, Cheol Hyun Chung, Jae Won Lee, Sung Ho Jung, Suk Jung Choo.   

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is an established treatment option in patients with cardiogenic shock and respiratory dysfunction. We assessed outcomes of ECMO, as well as predictors of ECMO weaning and survival, in patients treated in our institution over the past five years.
METHODS: We reviewed the records of 185 patients who received ECMO support for various medical conditions between January 2005 and January 2010. Risk factors for successful weaning, early mortality, and overall survival were investigated.
RESULTS: There were 101 males and 84 females, and the mean age was 56.1 ± 14.7 years. Patients received either venoarterial (n = 137) or veno-veno (n = 48) ECMO. ECMO was instituted in stable patients (n = 40, 21.6%), those in shock (n = 105, 56.8%), or those in cardiac arrest (n = 40, 21.6%). Mean ECMO support lasted 4.7 days and weaning was successful in 68 patients (36.7%), with 38 (20.5%) eventually being discharged from the hospital. Univariate analysis showed hemodynamic status at insertion (p = 0.05) including intra-aortic balloon pump usage to significantly influence successful weaning, whereas the duration of ECMO was strongly associated with overall survival (p = 0.05).
CONCLUSIONS: Early ECMO application before catastrophic clinical deterioration and weaning as soon as possible may enhance overall survival.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22364366     DOI: 10.1111/j.1540-8191.2011.01400.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  7 in total

1.  Nutrition support during extracorporeal membrane oxygenation (ECMO) in adults: a retrospective audit of 86 patients.

Authors:  Suzie Ferrie; Robert Herkes; Paul Forrest
Journal:  Intensive Care Med       Date:  2013-08-16       Impact factor: 17.440

2.  Predicting outcome of venovenous ECMO: look outside the lung!

Authors:  Federico Pappalardo; Martina Crivellari
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

3.  Long-term survival and major outcomes in post-cardiotomy extracorporeal membrane oxygenation for adult patients in cardiogenic shock.

Authors:  Paolo Meani; Matteo Matteucci; Federica Jiritano; Dario Fina; Francesco Panzeri; Giuseppe M Raffa; Mariusz Kowalewski; Nuccia Morici; Giovanna Viola; Alice Sacco; Fabrizio Oliva; Amal Alyousif; Sam Heuts; Martijn Gilbers; Rick Schreurs; Jos Maessen; Roberto Lorusso
Journal:  Ann Cardiothorac Surg       Date:  2019-01

4.  Prediction of mortality in adult patients with severe acute lung failure receiving veno-venous extracorporeal membrane oxygenation: a prospective observational study.

Authors:  Tone Enger; Alois Philipp; Vibeke Videm; Matthias Lubnow; Alexander Wahba; Marcus Fischer; Christof Schmid; Thomas Bein; Thomas Müller
Journal:  Crit Care       Date:  2014-04-09       Impact factor: 9.097

5.  Rescue extracorporeal membrane oxygenation for refractory cardiogenic shock.

Authors:  Paweł Litwiński; Artur Dębski; Paweł Tyczyński; Małgorzata Jasińska; Jerzy Lichomski; Jarosław Szymański; Mariusz Kuśmierczyk
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-01-12       Impact factor: 1.426

6.  Estimating cardiac output based on gas exchange during veno-arterial extracorporeal membrane oxygenation in a simulation study using paediatric oxygenators.

Authors:  Kaspar Felix Bachmann; Rakesh Vasireddy; Paul Philipp Heinisch; Hansjörg Jenni; Andreas Vogt; David Berger
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

7.  Gas exchange calculation may estimate changes in pulmonary blood flow during veno-arterial extracorporeal membrane oxygenation in a porcine model.

Authors:  Kaspar F Bachmann; Matthias Haenggi; Stephan M Jakob; Jukka Takala; Luciano Gattinoni; David Berger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-04-15       Impact factor: 5.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.